Abstract:
Objective: The objective of the present study was to evaluate the effect of
PPAR receptor modulators in experimentally induced inflammatory bowel
disease in rats, the effect of PPAR- (Fenofibrate) and PPAR-
(Pioglitazone) agonist individually and in combination and the effect of
Palmitoylethanolamide (combined PPAR- and agonist) as PPAR
modulator in treatment of inflammatory bowel disease.
Method: The Inflammatory bowel disease was induced by TNBS (30 mg in
0.25 ml of 50% ethanol), intrarectally. Animals were divided into 6 groups.
Group 1 (Model control), had received TNBS 30 mg in 0.25 ml of 50%
ethanol, intrarectally.
Group 2 (Standard Group), had received TNBS 30 mg in 0.25 ml of 50%
ethanol intrarectally + prednisolone, 10 mg/kg, p.o. for 21 days. Group 3
had received TNBS (30 mg in 0.25 ml of 50% ethanol), intrarectally +
Fenofibrate (100mg/kg, p.o.) after 24 hr of TNBS induction, for 21days.
Group 4 had received TNBS 30 mg in 0.25 ml of 50% ethanol, intrarectally
+ Pioglitazone (10mg/kg p.o.) after 24 hr of TNBS induction, For 21days.
Group 5 had received TNBS (30 mg in 0.25 ml of 50% ethanol), intrarectally
+ Fenofibrate (100 mg/kg p.o.) and Pioglitazone (10 mg/kg p.o) after 24 hr
of TNBS induction, for 21 days.
Group 6 had received TNBS (30 mg in 0.25 ml of 50% ethanol), intrarectally
+ Palmitoylethanolamide (PEA) (10 mg/kg p.o.) after 24 hr of TNBS
induction, for 21 days. On the 21st day of drug treatment, blood was
collected and biochemical parameters like NO, MPO, MDA, CRP, SOD
were estimated in all groups of animals. Result And Discussion: Fenofibrate (PPAR- agonist) and Pioglitazone
(PPAR- agonist) ameliorate colitis as in individual and in combination.
Palmitoylethanolamide (PPAR / agonist) also has around same effect as
that combination.
Conclusions: Combination of the PPAR receptor is significtally more
effective than the individual effect of PPAR and PPAR .
